Kenneth Lee - BioCryst Pharmaceuticals Independent Director
| BCRX Stock | USD 4.38 0.03 0.68% |
Director
Mr. Kenneth B. Lee, Jr., serves as an Independent Director of Biocryst Pharmaceuticals Inc. Mr. Lee was appointed to the Board in June 2011. Mr. Lee has over 40 years of experience counseling management teams, boards of directors and investors of technologybased companies worldwide. He is currently a General Partner with Hatteras Venture Partners, LLC, a VC fund focusing on life science companies, which he joined in 2003. Previously he was President of A.M. Pappas Associates, LLC, following 29 years with Ernst Young LLP, where he was most recently Managing Director of the firms health sciences corporate finance group, and at one time served as the National Director of the Life Sciences Practice. Mr. Lee received a Bachelor of Arts degree from LenoirRhyne College and an MBA from the University of North Carolina at Chapel Hill. Mr. Lee is currently on the Board of Directors of Aralez, Inc., and previously served on the Boards of private companies, Clinipace, Clinverse and A.M. Pappas Associates. Previously, Mr. Lee served on the Boards of Abgenix, Inc., CV Therapeutics, Inspire Pharmaceuticals, Maxygen, Inc., and OSI Pharmaceuticals. He has served in various leadership capacities on these Boards, including Chairman of the Board, Independent Lead Director and Chairman of Audit and Compensation Committees since 2011.
| Age | 70 |
| Tenure | 13 years |
| Address | 4505 Emperor Boulevard, Durham, NC, United States, 27703 |
| Phone | 919 859 1302 |
| Web | https://www.biocryst.com |
BioCryst Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1157) % which means that it has lost $0.1157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.52 in 2024, whereas Return On Tangible Assets are likely to drop (0.46) in 2024. At this time, BioCryst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 24.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 7.6 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kurt Graves | Seres Therapeutics | 50 | |
| Richard Sykes | PDS Biotechnology Corp | 76 | |
| Gregory Behar | Seres Therapeutics | 48 | |
| Michael Donnell | Cassava Sciences | 59 | |
| George Demetri | Blueprint Medicines Corp | 61 | |
| Murray Stewart | X4 Pharmaceuticals | 57 | |
| Daniel Hume | TG Therapeutics | 51 | |
| William Reardon | Madrigal Pharmaceuticals | 68 | |
| Maya Said | Pieris Pharmaceuticals | 40 | |
| Lonnel Coats | Blueprint Medicines Corp | 53 | |
| William Heiden | Atara Biotherapeutics | 58 | |
| Sinclair Dunlop | Apellis Pharmaceuticals | 46 | |
| Michael Richman | Pieris Pharmaceuticals | 53 | |
| Michael Sherman | Biovie Inc | N/A | |
| Ann Barbier | Pieris Pharmaceuticals | N/A | |
| Paul Friedman | Madrigal Pharmaceuticals | 75 | |
| Christina Takke | Pieris Pharmaceuticals | 44 | |
| Julian Adams | Pieris Pharmaceuticals | 62 | |
| James Daly | Madrigal Pharmaceuticals | N/A | |
| Willard Dere | Seres Therapeutics | 64 | |
| Jorg Neermann | Immunic | 47 | |
Management Performance
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.12 |
BioCryst Pharmaceuticals Leadership Team
Elected by the shareholders, the BioCryst Pharmaceuticals' board of directors comprises two types of representatives: BioCryst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCryst. The board's role is to monitor BioCryst Pharmaceuticals' management team and ensure that shareholders' interests are well served. BioCryst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCryst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rob Bennett, Vice President Investor Relations & Operations | ||
| Alane Barnes, VP, General Counsel and Corporate Secretary | ||
| Elliott Berger, VP Affairs | ||
| Stanley Erck, Independent Director | ||
| Robert Ingram, Director | ||
| William MBBS, Chief Officer | ||
| Stephanie Angelini, Chief Officer | ||
| Charles Sanders, Independent Director | ||
| Jon Stonehouse, CEO and President and Executive Director | ||
| Charles Gayer, Senior Officer | ||
| Kenneth Lee, Independent Director | ||
| Stephen Aselage, Director | ||
| William Sheridan, Senior Vice President Chief Medical Officer | ||
| Nancy Hutson, Independent Director | ||
| Yarlagadda Babu, Sr. VP of Drug Discovery | ||
| Fred Cohen, Director | ||
| George Abercrombie, Non-Executive Independent Chairman of the Board | ||
| Thomas Staab, CFO, Senior Vice President Principal Accounting Officer, Treasurer | ||
| Michael Jones, Executive Officer | ||
| Lynne Powell, Senior Vice President Chief Commercial Officer | ||
| John Bluth, IR Contact Officer | ||
| Megan Sniecinski, Chief Business Officer | ||
| Sanj Patel, Director | ||
| Theresa Heggie, Director | ||
| Anthony Doyle, Senior CFO | ||
| MD FAAP, Chief Officer |
BioCryst Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCryst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 1.37 B | ||||
| Shares Outstanding | 206.15 M | ||||
| Shares Owned By Insiders | 1.21 % | ||||
| Shares Owned By Institutions | 88.13 % | ||||
| Number Of Shares Shorted | 32.25 M | ||||
| Price To Earning | (7.11) X |
Pair Trading with BioCryst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with BioCryst Stock
| 0.73 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against BioCryst Stock
| 0.57 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.54 | OPT | Opthea | PairCorr |
| 0.52 | AVTE | Aerovate Therapeutics Financial Report 20th of May 2024 | PairCorr |
| 0.51 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.